The global pulmonary/respiratory drug delivery market reached $40.67 bn in 2018 and is expected to grow at a CAGR of 7.60% in 2019-2024. The MDIs segment is estimated to hold a share of 62.4% in 2018. Increasing prevalence and incidence of chronic respiratory diseases is a major factor that is expected to drive the growth of this market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 155-page report you will receive 70 tables and 84 figures– all unavailable elsewhere.

The 155-page report provides clear detailed insight into the global pulmonary/respiratory drug delivery market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Download Free Sample Pages of this report

Report Scope

Global Pulmonary/Respiratory Drug Delivery Market forecasts from 2019-2029

Global Pulmonary/Respiratory Drug Delivery Market forecasts from 2019-2029 by Product:

  • Formulation: Suspension Aerosol. Solution Aerosol, Dry Powder Formulation
  • Devices: Metered Dose Inhalers (MDIS), Dry Powder Inhalers (DPIS), Nebulizers, Accessories

Global Pulmonary/Respiratory Drug Delivery Market forecasts from 2019-2029 by Canister Type:

  • Plain Canisters
  • Coated Canister

Global Pulmonary/Respiratory Drug Delivery Market forecasts from 2019-2029 by Application:

  • Asthma
  • COPD
  • Cystic Fibrosis
  • Other Applications

Global Pulmonary/Respiratory Drug Delivery Market forecasts from 2019-2029 by End-User:

  • Hospitals & Clinics
  • Homecare Settings

Global Pulmonary/Respiratory Drug Delivery Market forecasts from 2018-2029 by regional and national market:

  • North America (US, Canada)
  • Europe (Germany, UK, France, Italy, Spain)
  • Asia-Pacific (Japan, China, India, Australia, Malaysia)
  • RoW (Brazil, Mexico, Turkey, South Africa, Argentina)

Profiles of the selected leading companies:

  • 3M Health Care
  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • OMRON Corporation
  • Philips Respironics
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical

Qualitative analysis of the global pulmonary/respiratory drug delivery market. Discussion on trends, factors that drive and restrain the market as well as Porter’s Five Forces Analysis.

Key Questions Answered by this Report:

  • What are the global revenue prospects for the period 2018 to 2029?
  • What are the leading national market potentials from 2018 to 2029?
  • How is the respiratory drug delivery market evolving?
  • What is driving and restraining the respiratory drug delivery market?
  • What are the market shares of each segment of the overall respiratory drug delivery market?
  • How will main respiratory drug delivery submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for each respiratory drug delivery submarket develop from 2018 to 2029?
  • What will be the main commercial drivers for the market from 2018 to 2029?
  • How will political and regulatory factors influence that industry and its submarkets?
  • How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?